Liraglutide combined with intense lifestyle modification in the management of obesity in adolescents
| Autor: | Lucy Gait, Peter Laing, Karen Erlandson-Parry, Senthil Senniappan, Louise Apperley |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pediatric Obesity
Pediatrics medicine.medical_specialty Adolescent Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism Childhood obesity Management of obesity 03 medical and health sciences 0302 clinical medicine Endocrinology Behavior Therapy Weight loss Weight management medicine Humans Hypoglycemic Agents 030212 general & internal medicine Lifestyle Therapy Exercise Life Style business.industry Separation anxiety disorder Liraglutide Prognosis medicine.disease Combined Modality Therapy Pediatrics Perinatology and Child Health Anxiety Female medicine.symptom business Body mass index Follow-Up Studies |
| Zdroj: | Journal of Pediatric Endocrinology and Metabolism. 34:613-618 |
| ISSN: | 2191-0251 0334-018X 2020-0714 |
| Popis: | Objectives Childhood obesity is a public health concern worldwide, with rates continuing to rise, despite preventive measures. Lifestyle modification remains the mainstay in the treatment of patients with excessive weight, but unfortunately, this is not always successful. Options for medical management of obesity in the paediatric population are limited. Methods Seven adolescents (all girls, mean age 14.9 years) with a body mass index (BMI) above 98th percentile and serious complications secondary to obesity were offered an intense weight management programme. The participants were reviewed by a multidisciplinary team every two weeks for advice and support, and treated with daily subcutaneous injections of liraglutide (dose range 1.2–3.0 mg). Scores for anxiety and depression were evaluated using the Revised Child Anxiety and Depression Scale. Results The results showed a significant weight loss over the three months with an average reduction of 5.4 kg (4.2%; 95% CI 1.93–8.78; p=0.0087). The mean drop in BMI was 2.1 kg/m2, which is statistically significant (95% CI 0.973–3.199; p=0.0037). Resolution of complications (raised intracranial pressure and steatohepatitis) was noted following weight loss. Anxiety and depressive symptoms improved over the three-month intervention course, especially features of separation anxiety disorder. Liraglutide was well tolerated by all patients. Conclusions Liraglutide medication, alongside a dedicated multidisciplinary team guided lifestyle therapy, is effective and safe in the treatment for excessive weight in adolescents, leading to the reversal of the complications related to obesity and improvement in the psychological symptoms. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|